Date: Sunday, June 12, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Background: Abnormal hepatic and systemic angiogenesis is an important component of advanced liver disease. Circulating hematopoietic progenitor cells (HPCs) and M2 monocytes are thought to contribute to angiogenesis. We aimed to determine the associations between circulating HPCs and M2 monocytes and the manifestations of end stage liver disease.
Methods: The Pulmonary Vascular Complications of Liver Disease (PVCLD2) study is a five-center prospective cohort study of patients being evaluated for liver transplantation and patients with portopulmonary hypertension. We excluded subjects with a diagnosis of hepatopulmonary syndrome or portopulmonary hypertension. Fasting blood samples were obtained and stored at room temperature until next-day analysis using flow cytometry. HPCs were defined as CD34+133+ mononuclear cells, and M2 monocytes were CD14+CD16+. We explored the association between the percentage of HPCs and M2 monocytes present and baseline demographics, liver disease etiology, liver disease severity and manifestations of decompensated disease.
Results: The study sample included 225 patients with available flow cytometry. HPCs and M2 monocytes were not associated with the etiology of liver disease. Higher HPC levels were significantly associated with the presence of ascites (p=0.08), a history of spontaneous bacterial peritonitis, (p=0.05), and presence of hepatic encephalopathy on examination (p=0.02). Patients with more significant disease severity had higher levels of HPCs (0.125 CTP A vs. 0.132 CTP B, vs. 0.183 CTP C, p=0.05). M2 monocyte levels were also significantly associated with a history of hepatic encephalopathy and variceal hemorrhage, there was no association with disease severity as measured by CTP or MELD score.
Conclusions: HPCs and M2 monocytes were associated with hepatic decompensation. These markers of angiogenesis in end stage liver disease could be useful biomarkers of targeted therapy.
CITATION INFORMATION: Forde K, Krok K, Patel M, Krowka M, Fallon M, Kawut S. Hematopoietic Progenitor Cells and Monocyte Subsets and Hepatic Decompensation in Patients Referred for Liver Transplant Evaluation. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Forde K, Krok K, Patel M, Krowka M, Fallon M, Kawut S. Hematopoietic Progenitor Cells and Monocyte Subsets and Hepatic Decompensation in Patients Referred for Liver Transplant Evaluation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/hematopoietic-progenitor-cells-and-monocyte-subsets-and-hepatic-decompensation-in-patients-referred-for-liver-transplant-evaluation/. Accessed March 8, 2021.
« Back to 2016 American Transplant Congress